Navigation Links
Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
Date:9/16/2011

r showing long-term QNEXA data on glycemic effects in type 2 diabetic patients (N=145) from the two-year SEQUEL study. In the SEQUEL diabetic sub-group, greater percent weight loss was achieved with QNEXA when compared to placebo at week 108 (9.0% in the mid- and top-dose QNEXA and 2.0% placebo within the diabetic sub-group P≤0.0003). Within the diabetic sub-group, improvements were seen in fasting glucose, fasting insulin and hemoglobin A1c in the QNEXA-treated groups. The QNEXA-treated patients also had reduced utilization of concomitant antidiabetic medications as compared to placebo (P=0.0130).  

A poster presentation by Dr. Hermann Toplak from the Medical University of Graz, Austria focused on long-term QNEXA treatment, sustained weight loss, reversal of metabolic syndrome and improvements in associated traits. Of the 675 patients enrolled in SEQUEL, 451 (66.8%) met the criteria for metabolic syndrome. Average percent weight loss at week 108 within the metabolic syndrome sub-group was 11.1% mid-dose QNEXA, 12.2% top-dose QNEXA and 2.8% placebo (P<0.0001 vs. placebo). The percentage of patients demonstrating resolution of metabolic syndrome was significantly higher within the QNEXA treatment arms at week 108 [22.4% mid-dose (P=0.0031), 27.6% top-dose (P<0.0001)] vs. 9.2% with placebo. Conversely, the percentage of patients without metabolic syndrome at baseline, who progressed to metabolic syndrome at week 108, were higher in the placebo group at 60% vs. 23% with top-dose QNEXA (P= 0.0050).In all three analyses, the safety profile was consistent across subpopulations and the most common adverse events seen were upper respiratory infection, constipation, tingling, runny nose and dry mouth.

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA
2. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
3. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
4. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
5. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
6. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
7. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
10. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... Spanien und CALGARY, Alberta , September ... Vorgestellt in der "State of the Art and Featured ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, ... bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 ... gehalten hat. In seinem Vortrag mit dem Titel " ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... June 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) today announced results from a ... BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall ... that produce insulin.) Three years of BYETTA therapy improved ...
... June 25 Novo Nordisk today presented phase 2 ... which demonstrated the potential to help achieve target glycemic control when ... at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) ... These ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 2Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 3
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Melatonin supplements did not reduce ... a new study found. Many older hospital patients ... to disruption of their normal sleep-wake cycle. A lack ... contributes to delirium, but there has been little research ... This study included 378 patients, average age 84, who ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... Albany, New York (PRWEB) September 02, 2014 ... lucrative business with products and services such as ... color, radio frequency-device based treatments, and breast augmentation ... market report published by U.S.-based market intelligence firm ... anti-aging treatments and products will grow to USD ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... now has nearly 400 million hectares of natural grassland, the ... its usable grassland has degraded to various extents and hence ... efforts to protect the country's grasslands. ,He said ... sustainable economic growth. , This is mainly done ...
... As a normal charge contraceptives have a VAT of 17.5% ... and other contraceptives in the ensuing budget.,Gordon Brown is due ... said by High Street chemist Superdrug which said that it ... to 5%. It said the move followed a successful 10-month ...
... - The radiation watchdog in Finland has decided to test ... human proteins by testing them directly on human skin in ... health.// ,A pilot study that is scheduled to ... skin on the participants' arms to cell phone radiation for ...
... product of rice processing, called rice bran, significantly lowers ... humans.// ,Journal of Agricultural and Food Chemistry, ... scientific society holds the nuances of the study. ... Brewing researchers’ showed that if rice ran is added ...
... motivator has been helping South Africans to improve their lives ... workshops in various cities seek to teach// people how to ... says lies between the conscious state and sleep. ... 10 percent of their mind power," Adhia told students at ...
... reported that women in India are gradually becoming more ... 40 percent of India’s infected population//. ,"Women ... disparities, lack of education and trafficking of women are ... the women's human rights and human security unit, United ...
Cached Medicine News:Health News:Biologically Women Are More Vulnerable To HIV Infection 2
Used to introduce large devices for vascular intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Portless Sheath Introducers...
Medicine Products: